Literature DB >> 14695331

Expression and activation of mitogen-activated protein kinase kinases-3 and -6 in rheumatoid arthritis.

Martine Chabaud-Riou1, Gary S Firestein.   

Abstract

The p38 mitogen-activated protein (MAP) kinase signal transduction pathway regulates the production of interleukin-1 and tumor necrosis factor-alpha. p38 kinase inhibitors are effective in animal models of arthritis and are currently being developed in rheumatoid arthritis (RA). However, little is known about the upstream kinases that control the activation of p38 in RA synovium. In vitro studies previously identified the MAP kinase kinases (MAPKKs) MKK3 and MKK6 as the primary regulators of p38 phosphorylation and activation. To investigate a potential role for MKK3 and MKK6 in RA, we evaluated their expression and regulation in RA synovium and cultured fibroblast-like synoviocytes (FLS). Immunohistochemistry demonstrated that MKK3 and MKK6 are expressed in RA and osteoarthritis (OA) synovium. Digital image analysis showed no significant differences between OA and RA with regard to expression or distribution. However, phosphorylated MKK3/6 expression was significantly higher in RA synovium and was localized to the sublining mononuclear cells and the intimal lining. Actin-normalized Western blot analysis of synovial tissue lysates confirmed the increased expression of phosphorylated MKK3/6 in RA. Western blot analysis demonstrated constitutive expression of MKK3 and MKK6 in RA and OA FLS. Phospho-MKK3 levels were low in medium-treated FLS, but were rapidly increased by interleukin-1 and tumor necrosis factor-alpha, although phospho-MKK6 levels only modestly increased. p38 co-immunoprecipitated with MKK3 and MKK6 from cytokine-stimulated FLS and the complex phosphorylated activating transcription factor-2 in an in vitro kinase assay. These data are the first documentation of MKK3 and MKK6 activation in human inflammatory disease. By forming a complex with p38 in synovial tissue and FLS, these kinases can potentially be targeted to regulate the production of proinflammatory cytokine production in inflamed synovium.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14695331      PMCID: PMC1602215          DOI: 10.1016/S0002-9440(10)63108-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

1.  Mammalian mitogen-activated protein kinase pathways are regulated through formation of specific kinase-activator complexes.

Authors:  B W Zanke; E A Rubie; E Winnett; J Chan; S Randall; M Parsons; K Boudreau; M McInnis; M Yan; D J Templeton; J R Woodgett
Journal:  J Biol Chem       Date:  1996-11-22       Impact factor: 5.157

Review 2.  Mitogen-activated protein kinase pathways.

Authors:  M J Robinson; M H Cobb
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

Review 3.  MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c-Jun amino-terminal kinases?

Authors:  G R Fanger; P Gerwins; C Widmann; M B Jarpe; G L Johnson
Journal:  Curr Opin Genet Dev       Date:  1997-02       Impact factor: 5.578

4.  MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway.

Authors:  J Raingeaud; A J Whitmarsh; T Barrett; B Dérijard; R J Davis
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

5.  Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases.

Authors:  M Goedert; A Cuenda; M Craxton; R Jakes; P Cohen
Journal:  EMBO J       Date:  1997-06-16       Impact factor: 11.598

6.  Regulation of interleukin-1beta-induced interleukin-6 gene expression in human fibroblast-like synoviocytes by p38 mitogen-activated protein kinase.

Authors:  K Miyazawa; A Mori; H Miyata; M Akahane; Y Ajisawa; H Okudaira
Journal:  J Biol Chem       Date:  1998-09-18       Impact factor: 5.157

7.  Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6.

Authors:  H Enslen; J Raingeaud; R J Davis
Journal:  J Biol Chem       Date:  1998-01-16       Impact factor: 5.157

8.  Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases.

Authors:  P Juo; C J Kuo; S E Reynolds; R F Konz; J Raingeaud; R J Davis; H P Biemann; J Blenis
Journal:  Mol Cell Biol       Date:  1997-01       Impact factor: 4.272

9.  A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3.

Authors:  T Moriguchi; N Kuroyanagi; K Yamaguchi; Y Gotoh; K Irie; T Kano; K Shirakabe; Y Muro; H Shibuya; K Matsumoto; E Nishida; M Hagiwara
Journal:  J Biol Chem       Date:  1996-06-07       Impact factor: 5.157

10.  SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes.

Authors:  A M Badger; M N Cook; M W Lark; T M Newman-Tarr; B A Swift; A H Nelson; F C Barone; S Kumar
Journal:  J Immunol       Date:  1998-07-01       Impact factor: 5.422

View more
  17 in total

1.  Decreased collagen-induced arthritis severity and adaptive immunity in MKK-6-deficient mice.

Authors:  Deepa Hammaker; Katharyn Topolewski; Meghan Edgar; Toshio Yoshizawa; Akihisa Fukushima; David L Boyle; Esther Cory Burak; Robert L Sah; Gary S Firestein
Journal:  Arthritis Rheum       Date:  2012-03

Review 2.  The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis.

Authors:  G Schett; J Zwerina; G Firestein
Journal:  Ann Rheum Dis       Date:  2007-09-07       Impact factor: 19.103

3.  Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression.

Authors:  Toshio Yoshizawa; Deepa Hammaker; David L Boyle; Maripat Corr; Richard Flavell; Roger Davis; Georg Schett; Gary S Firestein
Journal:  J Immunol       Date:  2009-06-26       Impact factor: 5.422

4.  Hck is a key regulator of gene expression in alternatively activated human monocytes.

Authors:  Ashish Bhattacharjee; Srabani Pal; Gerald M Feldman; Martha K Cathcart
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

Review 5.  Non-'classical' MEKs: A review of MEK3-7 inhibitors.

Authors:  Ada J Kwong; Karl A Scheidt
Journal:  Bioorg Med Chem Lett       Date:  2020-04-23       Impact factor: 2.823

6.  Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis.

Authors:  Tomoyuki Inoue; David L Boyle; Maripat Corr; Deepa Hammaker; Roger J Davis; Richard A Flavell; Gary S Firestein
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

Review 7.  "Go upstream, young man": lessons learned from the p38 saga.

Authors:  D Hammaker; G S Firestein
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

Review 8.  Pharmacogenetics: implications for therapy in rheumatic diseases.

Authors:  Lesley Davila; Prabha Ranganathan
Journal:  Nat Rev Rheumatol       Date:  2011-08-09       Impact factor: 20.543

9.  Update on Targets of Biologic Therapies for Rheumatoid Arthritis.

Authors:  Zafar Rasheed; Tariq M Haqqi
Journal:  Curr Rheumatol Rev       Date:  2008-11-01

10.  MKK3, an upstream activator of p38, contributes to formalin phase 2 and late allodynia in mice.

Authors:  L S Sorkin; D L Boyle; D Hammaker; D S Herman; E Vail; G S Firestein
Journal:  Neuroscience       Date:  2009-05-08       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.